355 related articles for article (PubMed ID: 10949779)
1. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
2. Large bowel adenomas: markers of risk and endpoints.
Baron JA
J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
[TBL] [Abstract][Full Text] [Related]
3. Problems with using biomarkers as surrogate end points for cancer: a cautionary tale.
Schatzkin A
Recent Results Cancer Res; 2005; 166():89-98. PubMed ID: 15648185
[TBL] [Abstract][Full Text] [Related]
4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
5. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
6. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers.
Hilsenbeck SG; Clark GM
J Cell Biochem Suppl; 1993; 17G():205-11. PubMed ID: 8007700
[TBL] [Abstract][Full Text] [Related]
8. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
9. The promise and peril of surrogate end points in cancer research.
Schatzkin A; Gail M
Nat Rev Cancer; 2002 Jan; 2(1):19-27. PubMed ID: 11902582
[TBL] [Abstract][Full Text] [Related]
10. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
11. Surrogate end points in cancer research: a critique.
Schatzkin A; Freedman LS; Dorgan J; McShane LM; Schiffman MH; Dawsey SM
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):947-53. PubMed ID: 8959315
[TBL] [Abstract][Full Text] [Related]
12. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
13. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers and surrogate endpoints in glaucoma clinical trials.
Medeiros FA
Br J Ophthalmol; 2015 May; 99(5):599-603. PubMed ID: 25034049
[TBL] [Abstract][Full Text] [Related]
15. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
16. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
Zhang Z; Pan Q; Lu M; Zhao B
EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.
Medeiros FA
Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO20-BIO26. PubMed ID: 28475699
[TBL] [Abstract][Full Text] [Related]
18. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
Tanaka S; Matsuyama Y; Ohashi Y
Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
[TBL] [Abstract][Full Text] [Related]
19. Surrogate endpoint analysis: an exercise in extrapolation.
Baker SG; Kramer BS
J Natl Cancer Inst; 2013 Mar; 105(5):316-20. PubMed ID: 23264679
[TBL] [Abstract][Full Text] [Related]
20. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
